Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.37 |
| ▸ | MAPT | P10636 | 4/20 | 0.37 |
| ▸ | TP53 | P04637 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | NPC1 | O15118 | 3/20 | 0.37 |
| ▸ | RAB9A | P51151 | 3/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | ACP1 | P24666 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL647757 | 0.93 | MAPT (0.43) | KDM4EMAPTTP53ALDH1A1NPC1 | |
| SCHEMBL648241 | 0.92 | RAB9A (0.44) | MAPTTP53ALDH1A1NPC1RAB9A | |
| SCHEMBL646800 | 0.91 | MAPT (0.45) | ADORA2AKDM4EMAPTTP53ALDH1A1 | |
| SCHEMBL645597 | 0.89 | MEN1 (0.44) | KDM4EMAPTTP53ALDH1A1NPC1 | |
| SCHEMBL646334 | 0.88 | MAPT (0.36) | KDM4EMAPTALDH1A1SMN1; SMN2HSD17B10 | |
| SCHEMBL646734 | 0.88 | MAPT (0.36) | KDM4EMAPTALDH1A1SMN1; SMN2HSD17B10 | |
| SCHEMBL645388 | 0.86 | STIM1 (0.40) | ALDH1A1SMN1; SMN2CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL645924 | 0.85 | ALDH1A1 (0.39) | ALDH1A1SMN1; SMN2HDAC1HDAC6 | |
| SCHEMBL647785 | 0.84 | STIM1 (0.40) | ADORA2AADORA1ALDH1A1SMN1; SMN2 | |
| SCHEMBL647018 | 0.84 | IL1B (0.38) | HSD17B10CYP1A2CYP3A4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8614321-B2 | Benzoimidazolyl-pyrazine compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2013-12-24 | — | — | US | disclosed |
| US-20120190853-A1 | BENZOIMIDAZOLYL-PYRAZINE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2012-07-26 | — | — | US | disclosed |
| US-20120190853-A1 | BENZOIMIDAZOLYL-PYRAZINE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2012-07-26 | — | — | US | disclosed |
| US-20120190853-A1 | BENZOIMIDAZOLYL-PYRAZINE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2012-07-26 | — | — | US | disclosed |
| US-8119643-B2 | Benzoimidazolyl-pyrazine compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2012-02-21 | — | — | US | disclosed |
| US-8119643-B2 | Benzoimidazolyl-pyrazine compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2012-02-21 | — | — | US | disclosed |
| US-8119643-B2 | Benzoimidazolyl-pyrazine compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2012-02-21 | — | — | US | disclosed |
| US-20070249609-A1 | Benzoimidazolyl-pyrazine compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. | 2007-10-25 | — | — | US | disclosed |
| US-20070249609-A1 | Benzoimidazolyl-pyrazine compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. | 2007-10-25 | — | — | US | disclosed |
| US-20070249609-A1 | Benzoimidazolyl-pyrazine compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. | 2007-10-25 | — | — | US | disclosed |
| WO-2007109362-A2 | BENZOIMIDAZOLYL-PARAZINE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2007-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120190853-A1 | BENZOIMIDAZOLYL-PYRAZINE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | IL5, CXCR5, NLRP3 | MKNK1 2455/4885ADORA2A 2029/4885ADORA1 1664/4885 |
| US-20070249609-A1 | Benzoimidazolyl-pyrazine compounds for inflammation and immune-related uses | IL5, CXCR5, NLRP3 | MKNK1 2455/4885ADORA2A 2029/4885ADORA1 1664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.